XARACOLL
Total Payments
$14.8M
Transactions
4,225
Doctors
2,592
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $5,433 | 77 | 63 |
| 2022 | $1.1M | 1,903 | 1,348 |
| 2021 | $13.7M | 2,129 | 1,522 |
| 2020 | $2,216 | 116 | 110 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.5M | 121 | 97.9% |
| Consulting Fee | $116,496 | 49 | 0.8% |
| Food and Beverage | $94,863 | 3,949 | 0.6% |
| Honoraria | $89,275 | 51 | 0.6% |
| Travel and Lodging | $15,818 | 55 | 0.1% |
Payments by Type
Research
$14.5M
121 transactions
General
$316,452
4,104 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | Innocoll Incorporated | $11.1M | 0 |
| An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | Innocoll Incorporated | $2.4M | 0 |
| An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries | Innocoll Pharmaceuticals Limited | $863,171 | 0 |
| Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair | Innocoll Pharmaceuticals Limited | $61,043 | 0 |
| Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty | Innocoll Pharmaceuticals Limited | $59,622 | 0 |
| A Multicenter Randomized Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics and Analgesic Effect of the INL-001 Bupivacaine Hydrochloride (HCl) Collagen-Matrix Implant in Children 2 to <17 Years of Age Following Open Inguinal | Innocoll Incorporated | $13,698 | 0 |
Top Doctors Receiving Payments for XARACOLL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $14.5M | 121 |
| Jarrod Kaufman | — | Brick, NJ | $58,726 | 75 |
| , MD | Internal Medicine | Winston-Salem, NC | $42,331 | 5 |
| , M.D | Surgery | Rincon, GA | $21,117 | 32 |
| , DO, MS | Surgery | Sparks, NV | $15,629 | 25 |
| , M.D | Surgery | Bryn Mawr, PA | $9,524 | 7 |
| , M.D | Internal Medicine | Ashton, MD | $9,100 | 7 |
| , MD | Internal Medicine | Boston, MA | $8,000 | 1 |
| , M.D | Anesthesiology | Philadelphia, PA | $7,425 | 1 |
| , MD | Surgery | Daytona Beach, FL | $4,245 | 3 |
| , MD | Surgery | Philadelphia, PA | $3,375 | 1 |
| , M.D | Surgery | Philadelphia, PA | $3,000 | 3 |
| , M.D | Surgery | Tampa, FL | $2,640 | 4 |
| , M.D | Orthopaedic Surgery | Columbia, MD | $2,600 | 1 |
| , M.D | Adult Reconstructive Orthopaedic Surgery | New York, NY | $2,600 | 1 |
| , MD | Internal Medicine | Boston, MA | $2,600 | 1 |
| , MD | Surgery | Boston, MA | $2,600 | 1 |
| , M.D | Adult Reconstructive Orthopaedic Surgery | New York, NY | $2,600 | 1 |
| Paul Lachiewicz | — | Chapel Hill, NC | $2,600 | 1 |
| , MD | Hematology & Oncology | Boston, MA | $2,600 | 1 |
| , MD | Orthopaedic Surgery | Philadelphia, PA | $2,600 | 1 |
| , M.D | Anesthesiology | Las Vegas, NV | $2,400 | 1 |
| , M.D | Internal Medicine | New York, NY | $1,750 | 1 |
| , M.D | Surgery | Jefferson City, MO | $1,350 | 1 |
| , M.D | Specialist | Newark, DE | $1,191 | 2 |
Ad
Manufacturing Companies
- Innocoll Incorporated $13.7M
- Innocoll Pharmaceuticals Limited $1.1M
- Mallinckrodt Hospital Products Inc. $7,876
Product Information
- Type Drug
- Total Payments $14.8M
- Total Doctors 2,592
- Transactions 4,225
About XARACOLL
XARACOLL is a drug associated with $14.8M in payments to 2,592 healthcare providers, recorded across 4,225 transactions in the CMS Open Payments database. The primary manufacturer is Innocoll Incorporated.
Payment data is available from 2020 to 2023. In 2023, $5,433 was paid across 77 transactions to 63 doctors.
The most common payment nature for XARACOLL is "Unspecified" ($14.5M, 97.9% of total).
XARACOLL is associated with 6 research studies, including "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty" ($11.1M).